<SEC-DOCUMENT>0001193125-21-367926.txt : 20211228
<SEC-HEADER>0001193125-21-367926.hdr.sgml : 20211228
<ACCEPTANCE-DATETIME>20211228160549
ACCESSION NUMBER:		0001193125-21-367926
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20211228
DATE AS OF CHANGE:		20211228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celularity Inc
		CENTRAL INDEX KEY:			0001752828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831702591
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258600
		FILM NUMBER:		211525028

	BUSINESS ADDRESS:	
		STREET 1:		1325 AVENUE OF THE AMERICAS
		STREET 2:		25TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		2126163700

	MAIL ADDRESS:	
		STREET 1:		1325 AVENUE OF THE AMERICAS
		STREET 2:		25TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GX Acquisition Corp.
		DATE OF NAME CHANGE:	20180912
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d466523d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS SUPPLEMENT No.&nbsp;7</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>(to Prospectus dated August&nbsp;12, 2021)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-258600</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g466523dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 22,874,999 Shares of Class&nbsp;A Common Stock Issuable Upon Exercise of Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 129,858,855 Shares of Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 8,499,999 Warrants to Purchase Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus, dated August&nbsp;12, 2021 (the &#147;Prospectus&#148;), which forms a part of our
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-258600).</FONT> This prospectus supplement is being filed to update and supplement the information in the Prospectus with the
information contained in our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on December&nbsp;28, 2021 (the &#147;Current Report&#148;). Accordingly, we have attached the Current
Report to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement relate to the issuance by us of an aggregate of up to
22,874,999 shares of our Class&nbsp;A common stock, $0.0001 par value per share (the &#147;Class&nbsp;A Common Stock&#148;), which consists of (i)&nbsp;the issuance by us and resale of up to 8,499,999 shares of Class&nbsp;A Common Stock that are
issuable upon the exercise of (A) 7,000,000 warrants issued in a private placement to GX Sponsor LLC (the &#147;Sponsor&#148;), in connection with the GX IPO and (B) 1,499,999 warrants issued to certain members of the Sponsor as repayment for
certain working capital loans made to GX (the warrants in (A)&nbsp;and (B) collectively, the &#147;Private Placement Warrants&#148;), and (ii)&nbsp;up to 14,375,000 shares of Class&nbsp;A Common Stock that are issuable upon the exercise of
14,375,000 warrants (the &#147;Public Warrants,&#148; and, together with the Private Placement Warrants, the &#147;Warrants&#148;) issued in the GX IPO. We will receive the proceeds from the exercise of any Warrants for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement also relates to the offer and sale from time to time by the selling securityholders named in the
Prospectus or their permitted transferees (the &#147;selling securityholders&#148;) of (i)&nbsp;up to 129,858,855 shares of Class&nbsp;A Common Stock consisting of (a)&nbsp;up to 8,340,000 shares of Class&nbsp;A Common Stock issued in a private
placement pursuant to subscription agreements (&#147;Subscription Agreements&#148;) entered into on January&nbsp;8, 2021 (b) up to 2,000,000 shares of Class&nbsp;A Common Stock issued in a private placement pursuant to a subscription agreement
entered into on May&nbsp;5, 2021 with Palantir Technologies Inc. (&#147;Palantir Technologies&#148;), (c) up to 976,943 shares of Class&nbsp;A Common Stock issued in private placements on July&nbsp;21, 2021 to certain advisors of Legacy Celularity
and GX, (d)&nbsp;up to 7,187,500 shares of Class&nbsp;A Common Stock previously held by the Sponsor following a private placement in connection with the initial public offering of GX, (e)&nbsp;up to 8,499,999 shares of Class&nbsp;A Common Stock
issuable upon exercise of the Private Placement Warrants, (f)&nbsp;up to 19,811,204 shares of Class&nbsp;A Common Stock issuable upon exercise of the Converted Legacy Warrants, (g)&nbsp;up to 11,744,882 shares of Class&nbsp;A Common Stock issuable
upon exercise of options and awards and (h)&nbsp;up to 71,298,327 shares of Class&nbsp;A Common Stock pursuant to that certain Registration Rights Agreement (the &#147;Registration Rights Agreement&#148;), dated July&nbsp;16, 2021, between us and
certain selling securityholders granting such holders registration rights with respect to such shares, and (ii)&nbsp;up to 8,499,999 Private Placement Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A Common Stock and Public Warrants are listed on The Nasdaq Stock Market LLC under the symbols &#147;CELU&#148; and
&#147;CELUW&#148;, respectively. On December&nbsp;27, 2021, the last reported sales price of Class&nbsp;A Common Stock was $5.01 per share and the last reported sales price of our Public Warrants was $0.79 per warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements thereto, which is to be
delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and
supersedes the information contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not complete without, and may not be delivered or utilized
except in connection with, the Prospectus, including any amendments or supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a
high degree of risk. You should review carefully the risks and uncertainties described in the section titled &#147;</B><B><I>Risk Factors</I></B><B>&#148; beginning on page 8 of the Prospectus, and under similar headings in any amendments or
supplements to the Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities, or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus supplement dated December&nbsp;28, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;27, 2021 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CELULARITY INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38914</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-1702591</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File&nbsp;Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>170 Park Ave,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Florham Park, NJ</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>07932</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (847)
<FONT STYLE="white-space:nowrap">562-4300</FONT> </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Class&nbsp;A Common Stock, $0.0001 par value per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CELU</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Warrants, each exercisable for one share of Class&nbsp;A Common Stock at an exercise price of $11.50 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CELUW</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;27, 2021, Celularity Inc. issued a press release announcing the receipt of Fast Track Designation from the U.S. Food and Drug Administration,
for its <FONT STYLE="white-space:nowrap">non-genetically</FONT> modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, <FONT STYLE="white-space:nowrap">CYNK-001,</FONT> in development for the treatment of
acute myeloid leukemia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by reference herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Celularity Inc. dated December&nbsp;27, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: December&nbsp;28, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CELULARITY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Keary Dunn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Keary Dunn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g466523dsp2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy
<FONT STYLE="white-space:nowrap">CYNK-001</FONT> in Development for the Treatment of AML </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FLORHAM PARK, N.J., &#150; December&nbsp;27,
2021&nbsp;&#151;&nbsp;Celularity Inc. (Nasdaq: CELU) (&#147;Celularity&#148;), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted
Fast Track Designation for its <FONT STYLE="white-space:nowrap">non-genetically</FONT> modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, <FONT STYLE="white-space:nowrap">CYNK-001,</FONT> in
development for the treatment of acute myeloid leukemia (AML). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The majority of patients with AML continue to have poor long-term outcomes,
particularly those who suffer relapse or have measurable residual disease, necessitating development of novel therapies, including <FONT STYLE="white-space:nowrap">CYNK-001,&#148;</FONT> said Andrew Pecora, M.D., President of Celularity. Robert
Hariri, M.D., Ph.D., Founder, Chairperson and Chief Executive Officer of Celularity added, &#147;We believe that the unique properties of our cell source, including the ability to proliferate and maintain activity, could be the key to improving
response rates and durability for patients. We are pleased to receive this fast-track designation from the FDA for AML supporting continued development of our placental-derived NK cell platform. <FONT STYLE="white-space:nowrap">CYNK-001</FONT>
previously received orphan drug designation for malignant gliomas and fast track designation for glioblastoma multiforme.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Fast Track
Designation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast Track Designation is an FDA process designed to facilitate the development and expedite the review of new drugs that are intended to
treat a serious condition and have the potential to address unmet medical needs. The purpose of Fast Track designation is to expedite the process of getting important new drugs to patients. The designation may offer frequent interactions with the
FDA review team on the product&#146;s development and the product may be eligible for rolling review and priority review if certain criteria are met.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">CYNK-001</FONT></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Celularity&#146;s lead therapeutic program based on its placental-derived unmodified NK cell type is <FONT STYLE="white-space:nowrap">CYNK-001,</FONT> an
allogeneic unmodified NK cell being developed as a treatment for hematologic malignancies, solid tumors, and infectious diseases. <FONT STYLE="white-space:nowrap">CYNK-001</FONT> is a cryopreserved allogeneic <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> cell therapy enriched for <FONT STYLE="white-space:nowrap">CD56+/CD3-</FONT> NK cells expanded from human placental CD34+ cells. The safety and efficacy of
<FONT STYLE="white-space:nowrap">CYNK-001</FONT> have not been established, and <FONT STYLE="white-space:nowrap">CYNK-001</FONT> has not been approved for any use by the U.S. Food and Drug Administration or any other analogous regulatory authority.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Celularity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Celularity Inc. (Nasdaq: CELU)
headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, <FONT
STYLE="white-space:nowrap">T-cells</FONT> engineered with a CAR (CAR <FONT STYLE="white-space:nowrap">T-cells),</FONT> and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and
degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta&#146;s unique biology and ready availability, it can
develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g466523dsp2.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To learn more, visit celularity.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes
&#147;forward-looking statements&#148; within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended. All statements other than statements of historical facts are &#147;forward-looking statements,&#148; including those relating to future events. In some cases, you can identify forward-looking statements by
terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;forecast,&#148; &#147;intends,&#148; &#147;may,&#148;
&#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;strive,&#148; &#147;target,&#148; &#147;will,&#148;
&#147;would&#148; and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include, statements regarding the ability to improve response
rates and durability, and other statements regarding the development of <FONT STYLE="white-space:nowrap">CYNK-001,</FONT> and Celularity&#146;s ability to develop effective, accessible and affordable therapies, among others. Many factors could cause
actual results to differ materially from those described in these forward-looking statements, including but not limited to: the inherent risks in biotechnological development, including with respect to the development of novel cellular therapies,
and the clinical trial and regulatory approval process; and risks associated with developments relating to Celularity&#146;s competitors and industry, along with those risk factors set forth under the caption &#147;Risk Factors&#148; in
Celularity&#146;s proxy statement/prospectus filed with the Securities and Exchange Commission (SEC) on August&nbsp;12, 2021 and other filings with the SEC. These risks and uncertainties may be amplified by the COVID- 19 pandemic. If any of these
risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that
Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity&#146;s current expectations, plans,
or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity&#146;s
views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may
be required under applicable securities laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celularity Investor Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlos Ramirez SVP, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Celularity Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">carlos.ramirez@celularity.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g466523dsp2.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celularity Media Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason Braco, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jbraco@lifescicomms.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g466523dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g466523dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^HKO*1Z9\(=:BM[J[TF5@IF DBR>I'!'Z_I7DXJGU$SUY6!/%><DTR1]4(*
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M<"I--@P* %H * "@ H * "@ H * "@ H * "@ (S0 8'I0 F!B@!, =J %
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M1$T+0;;3T7&Q<R'U8\G_ #]*RG+F=Q&Y4B"@ H 0"E:VPP I*X!CFG8 Q18
MQ19"#%)*P!S5 &*!ABE:VP!BDD(,4):@%4 8J>5 &#3:TT ,4K, IV ,4P%H
M 0T  Z4F 8I6 ,>U-^0",#M.!22 X=/#&HWWQ!.M:DG^BVZ;;9<J0/KSG]!U
MK=.*C89W !%9,!U @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
5 * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g466523dsp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g466523dsp2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M9,<L\I7)^BXQ7FRQ=1O0FYG:W\(].F@+Z-/):SCG9*2Z-[>H^O/TJX8V2=I
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M 8 K2I/G=[6!G-^-88M<U_0O#A@60/(;J=B.4B7T],GBMJ'N0E,$=NBA%"J
M% P .U<M[O4!U @H * "@ H * "@ H * "@ H * "@ H * (39VIO!>&VB-T
4J>6)B@WA>NW=UQ[4[M*P$U(#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
